Hit enter to search or ESC to close
SGX:S08 (Singapore Post Ltd) Singapore Post (SingPost) may be keen to unlock value by selling its flagship SingPost Centre, but market sentiment suggests now may not be the right time. The group’s share price...
🏢 CapitaLand’s Ascott Eyes Bigger Stage as CLI Scales Fund Management in China SGX:C38U (CapitaLand Investment Limited – CLI) When CapitaLand restructured in 2021, carving out CapitaLand Investment (CLI) to focus on real asset...
📈 Singtel Posts $4.02B FY2025 Profit, Powered by HQ Divestment & Operational Gains Z74.SI (Singapore Telecommunications Ltd) Singtel (Z74.SI) has reported a 405% year-on-year surge in FY2025 net profit to S$4.02 billion, boosted by...
🚨 From Boardroom Battles to Billion-Dollar Buyouts: SG Market on Fire! 🔥 SGX: CEDU 👀 Drama at Dasin Retail Trust! Trustee-manager claps back at ex-director Zhang Zhongming’s claims of being ignored and mismanagement. Says...
1. Wall Street Wrap Wall St ends the week flying high! SPX +0.70%, IXIC +0.52%, DJI +0.78%. Weekly gains? Nasdaq +7.2% S&P +5.3% Dow +3.4% Tech flexed: NVDA +16% META +8% AAPL +6% MSFT...
Healthcare S-REITs have emerged as the top-performing sub-sector in 2025, delivering an average total return of 6.2% year-to-date—significantly outperforming the broader iEdge S-REIT Index, which fell 1.1%. Over one- and three-year periods, the...
Genting Singapore (SGX: G13) remains undervalued despite posting weaker earnings and the surprise announcement that CEO Tan Hee Teck will step down on May 31, according to analysts. The company reported a 20% drop...
At least five companies from mainland China and Hong Kong are exploring IPOs, dual listings, or share placements on the Singapore Exchange (SGX) over the next 12 to 18 months, according to four sources...
1. IPO Details Purpose of IPO: Mirxes aims to raise approximately HKD 1.086 billion (USD 139 million) through its IPO. The proceeds are intended to support the commercialization of its gastric cancer test, further...
IPO Details Purpose of IPO: Hengrui Pharma aims to raise up to HK$9.89 billion (US$1.27 billion) through its Hong Kong listing. The proceeds are allocated as follows: Approximately 45% for funding clinical studies of...
